{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:34:37Z","timestamp":1791426877575,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sunitinib, a VEGF blockade, is used to treat clear cell renal cell carcinoma (ccRCC). However, the anti-cancer treatment effects of sunitinib do not last long in ccRCC patients. Ginsenoside, a natural medicine extracted from ginseng, has been studied in cancer treatment and shown to have anti-tumor effects and low toxicity. We assessed cell viability and cell cycle analysis in ccRCC cell lines after treatment with ginsenoside and sunitinib. DNA damage was evaluated by measuring 8-OHdG levels and comet assay. ROS levels, reflecting the cause of oxidative stress, were also measured. Ginsenoside significantly enhanced the inhibition of cell viability by sunitinib, a result that was also confirmed in the xenograft model. In cell cycle analysis, combination treatment of ginsenoside and sunitinib enhanced G2M arrest in comparison with single-treatment groups. In addition, DNA damage was increased by ginsenoside and sunitinib according to the comet assay, and the level of 8-OHdG, which reflects oxidative DNA damage, also increased. We verified that ginsenoside enhances the efficacy of sunitinib to inhibit the proliferation of ccRCC cells via induction of oxidative DNA damage. The combination therapy of sunitinib and ginsenoside suggested the possibility of effectively treating ccRCC patients.<\/jats:p>","DOI":"10.1038\/s41598-022-20075-0","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T05:04:14Z","timestamp":1668661454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Hyun Ji","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Hwi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Sang","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"20075_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354\u2013366. https:\/\/doi.org\/10.1056\/NEJMra1601333 (2017).","journal-title":"N. Engl. J. Med."},{"key":"20075_CR2","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.8493574","volume":"260","author":"F Latif","year":"1993","unstructured":"Latif, F. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317\u20131320. https:\/\/doi.org\/10.1126\/science.8493574 (1993).","journal-title":"Science"},{"key":"20075_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research, N","year":"2013","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349. https:\/\/doi.org\/10.1038\/nature12222 (2013).","journal-title":"Nature"},{"key":"20075_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85\u201390. https:\/\/doi.org\/10.1038\/ng0594-85 (1994).","journal-title":"Nat. Genet."},{"key":"20075_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s1535-6108(02)00240-4","volume":"3","author":"FA Mack","year":"2003","unstructured":"Mack, F. A. et al. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3, 75\u201388. https:\/\/doi.org\/10.1016\/s1535-6108(02)00240-4 (2003).","journal-title":"Cancer Cell"},{"key":"20075_CR6","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","volume":"14","author":"ML Nickerson","year":"2008","unstructured":"Nickerson, M. L. et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726\u20134734. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4921 (2008).","journal-title":"Clin. Cancer Res."},{"key":"20075_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002312","volume":"7","author":"LE Moore","year":"2011","unstructured":"Moore, L. E. et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 7, e1002312. https:\/\/doi.org\/10.1371\/journal.pgen.1002312 (2011).","journal-title":"PLoS Genet."},{"key":"20075_CR8","doi-asserted-by":"publisher","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","volume":"13","author":"WG Kaelin Jr","year":"2007","unstructured":"Kaelin, W. G. Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680s\u2013684s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1865 (2007).","journal-title":"Clin. Cancer Res."},{"key":"20075_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. & Kaelin, W. G. Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519\u20131530. https:\/\/doi.org\/10.1038\/s41591-020-1093-z (2020).","journal-title":"Nat. Med."},{"key":"20075_CR10","first-page":"188","volume":"20","author":"L Wan","year":"2015","unstructured":"Wan, L. et al. Expression and significance of FOXP1, HIF-1a and VEGF in renal clear cell carcinoma. J. BUON 20, 188\u2013195 (2015).","journal-title":"J. BUON"},{"key":"20075_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-018-0906-x","volume":"17","author":"W Zhai","year":"2018","unstructured":"Zhai, W. et al. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4\/SMAD7 signals. Mol. Cancer 17, 157. https:\/\/doi.org\/10.1186\/s12943-018-0906-x (2018).","journal-title":"Mol. Cancer"},{"key":"20075_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbcan.2014.11.002","volume":"1855","author":"SC Joosten","year":"2015","unstructured":"Joosten, S. C. et al. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim. Biophys. Acta 1855, 1\u201316. https:\/\/doi.org\/10.1016\/j.bbcan.2014.11.002 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"20075_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ejca.2013.08.021","volume":"50","author":"AM Molina","year":"2014","unstructured":"Molina, A. M. et al. Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. Eur. J. Cancer 50, 351\u2013358. https:\/\/doi.org\/10.1016\/j.ejca.2013.08.021 (2014).","journal-title":"Eur. J. Cancer"},{"key":"20075_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3892\/ijmm.2017.2857","volume":"39","author":"M Sun","year":"2017","unstructured":"Sun, M. et al. Anticancer effects of ginsenoside Rg3 (Review). Int. J. Mol. Med. 39, 507\u2013518. https:\/\/doi.org\/10.3892\/ijmm.2017.2857 (2017).","journal-title":"Int. J. Mol. Med."},{"key":"20075_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/157016109788340767","volume":"7","author":"JM Lu","year":"2009","unstructured":"Lu, J. M., Yao, Q. & Chen, C. Ginseng compounds: An update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol. 7, 293\u2013302. https:\/\/doi.org\/10.2174\/157016109788340767 (2009).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"20075_CR16","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1142\/S0192415X19500848","volume":"47","author":"D Jeong","year":"2019","unstructured":"Jeong, D. et al. Ginsenoside Rh2 suppresses breast cancer cell proliferation by epigenetically regulating the long noncoding RNA C3orf67-AS1. Am. J. Chin. Med. 47, 1643\u20131658. https:\/\/doi.org\/10.1142\/S0192415X19500848 (2019).","journal-title":"Am. J. Chin. Med."},{"key":"20075_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109483","volume":"120","author":"T Liu","year":"2019","unstructured":"Liu, T. et al. Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1\/P53BP1 pathway. Biomed. Pharmacother. 120, 109483. https:\/\/doi.org\/10.1016\/j.biopha.2019.109483 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"20075_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3892\/ijo.2017.4183","volume":"52","author":"YC Tang","year":"2018","unstructured":"Tang, Y. C. et al. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo. Int. J. Oncol. 52, 127\u2013138. https:\/\/doi.org\/10.3892\/ijo.2017.4183 (2018).","journal-title":"Int. J. Oncol."},{"key":"20075_CR19","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.3892\/etm.2020.8543","volume":"19","author":"G Zhang","year":"2020","unstructured":"Zhang, G., He, L., Chen, J., Xu, B. & Mao, Z. Ginsenoside Rh2 activates alpha-catenin phosphorylation to inhibit lung cancer cell proliferation and invasion. Exp. Ther. Med. 19, 2913\u20132922. https:\/\/doi.org\/10.3892\/etm.2020.8543 (2020).","journal-title":"Exp. Ther. Med."},{"key":"20075_CR20","doi-asserted-by":"publisher","DOI":"10.1590\/fst.124121","author":"H Li","year":"2022","unstructured":"Li, H., Wang, T., Cui, W., Gao, Z. & Che, Z. Effect of ginsenoside Rg3 on proliferation and apoptosis of 786-0 cells and AktmTORSTAT3 signaling in renal carcinoma. Food Sci. Technol. https:\/\/doi.org\/10.1590\/fst.124121 (2022).","journal-title":"Food Sci. Technol."},{"key":"20075_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc2716","volume":"9","author":"DW Meek","year":"2009","unstructured":"Meek, D. W. Tumour suppression by p53: A role for the DNA damage response?. Nat. Rev. Cancer 9, 714\u2013723. https:\/\/doi.org\/10.1038\/nrc2716 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"20075_CR22","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1126\/science.281.5383.1674","volume":"281","author":"S Banin","year":"1998","unstructured":"Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674\u20131677. https:\/\/doi.org\/10.1126\/science.281.5383.1674 (1998).","journal-title":"Science"},{"key":"20075_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-p","volume":"75","author":"WS El-Deiry","year":"1993","unstructured":"El-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817\u2013825. https:\/\/doi.org\/10.1016\/0092-8674(93)90500-p (1993).","journal-title":"Cell"},{"key":"20075_CR24","doi-asserted-by":"publisher","first-page":"8128","DOI":"10.1038\/sj.onc.1207994","volume":"23","author":"AJ Poole","year":"2004","unstructured":"Poole, A. J., Heap, D., Carroll, R. E. & Tyner, A. L. Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon. Oncogene 23, 8128\u20138134. https:\/\/doi.org\/10.1038\/sj.onc.1207994 (2004).","journal-title":"Oncogene"},{"key":"20075_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/978-1-61779-998-3_40","volume":"920","author":"A Sharma","year":"2012","unstructured":"Sharma, A., Singh, K. & Almasan, A. Histone H2AX phosphorylation: A marker for DNA damage. Methods Mol. Biol. 920, 613\u2013626. https:\/\/doi.org\/10.1007\/978-1-61779-998-3_40 (2012).","journal-title":"Methods Mol. Biol."},{"key":"20075_CR26","doi-asserted-by":"publisher","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Marechal","year":"2013","unstructured":"Marechal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 5, a012716. https:\/\/doi.org\/10.1101\/cshperspect.a012716 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"20075_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","volume":"11","author":"HC Reinhardt","year":"2007","unstructured":"Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175\u2013189. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.024 (2007).","journal-title":"Cancer Cell"},{"key":"20075_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/10590500902885684","volume":"27","author":"A Valavanidis","year":"2009","unstructured":"Valavanidis, A., Vlachogianni, T. & Fiotakis, C. 8-hydroxy-2\u2019 -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health 27, 120\u2013139. https:\/\/doi.org\/10.1080\/10590500902885684 (2009).","journal-title":"J. Environ. Sci. Health"},{"key":"20075_CR29","first-page":"440","volume":"42","author":"T Hemnani","year":"1998","unstructured":"Hemnani, T. & Parihar, M. S. Reactive oxygen species and oxidative DNA damage. Indian J. Physiol. Pharmacol. 42, 440\u2013452 (1998).","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"20075_CR30","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C Lopez-Otin","year":"2013","unstructured":"Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. Cell 153, 1194\u20131217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039 (2013).","journal-title":"Cell"},{"key":"20075_CR31","doi-asserted-by":"publisher","first-page":"2325391","DOI":"10.1155\/2020\/2325391","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Ginsenoside-Rg1 rescues stress-induced depression-like behaviors via suppression of oxidative stress and neural inflammation in rats. Oxid. Med. Cell Longev. 2020, 2325391. https:\/\/doi.org\/10.1155\/2020\/2325391 (2020).","journal-title":"Oxid. Med. Cell Longev."},{"key":"20075_CR32","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12272-021-01345-3","volume":"44","author":"H Jeon","year":"2021","unstructured":"Jeon, H., Jin, Y., Myung, C. S. & Heo, K. S. Ginsenoside-Rg2 exerts anti-cancer effects through ROS-mediated AMPK activation associated mitochondrial damage and oxidation in MCF-7 cells. Arch. Pharm. Res. 44, 702\u2013712. https:\/\/doi.org\/10.1007\/s12272-021-01345-3 (2021).","journal-title":"Arch. Pharm. Res."},{"key":"20075_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.15430\/jcp.2013.18.2.177","volume":"18","author":"BM Kim","year":"2013","unstructured":"Kim, B. M., Kim, D. H., Park, J. H., Na, H. K. & Surh, Y. J. Ginsenoside Rg3 induces apoptosis of human breast cancer (MDA-MB-231) cells. J. Cancer Prev. 18, 177\u2013185. https:\/\/doi.org\/10.15430\/jcp.2013.18.2.177 (2013).","journal-title":"J. Cancer Prev."},{"key":"20075_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3892\/ol.2018.9691","volume":"17","author":"Y Peng","year":"2019","unstructured":"Peng, Y. et al. Ginsenoside Rg3 suppresses the proliferation of prostate cancer cell line PC3 through ROS-induced cell cycle arrest. Oncol. Lett. 17, 1139\u20131145. https:\/\/doi.org\/10.3892\/ol.2018.9691 (2019).","journal-title":"Oncol. Lett."},{"key":"20075_CR35","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12513","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Ginsenoside Rh2 stimulates the production of mitochondrial reactive oxygen species and induces apoptosis of cervical cancer cells by inhibiting mitochondrial electron transfer chain complex. Mol. Med. Rep. https:\/\/doi.org\/10.3892\/mmr.2021.12513 (2021).","journal-title":"Mol. Med. Rep."},{"key":"20075_CR36","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/cancers12082051","volume":"12","author":"A Moretton","year":"2020","unstructured":"Moretton, A. & Loizou, J. I. Interplay between cellular metabolism and the DNA damage response in cancer. Cancers 12, 2051. https:\/\/doi.org\/10.3390\/cancers12082051 (2020).","journal-title":"Cancers"},{"key":"20075_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0921-8734(92)90036-o","volume":"275","author":"M Dizdaroglu","year":"1992","unstructured":"Dizdaroglu, M. Oxidative damage to DNA in mammalian chromatin. Mutat. Res. 275, 331\u2013342. https:\/\/doi.org\/10.1016\/0921-8734(92)90036-o (1992).","journal-title":"Mutat. Res."},{"key":"20075_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/s1383-5742(97)00035-5","volume":"387","author":"H Kasai","year":"1997","unstructured":"Kasai, H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2\u2019-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat. Res. 387, 147\u2013163. https:\/\/doi.org\/10.1016\/s1383-5742(97)00035-5 (1997).","journal-title":"Mutat. Res."},{"key":"20075_CR39","doi-asserted-by":"publisher","first-page":"19633","DOI":"10.1074\/jbc.272.32.19633","volume":"272","author":"KB Beckman","year":"1997","unstructured":"Beckman, K. B. & Ames, B. N. Oxidative decay of DNA. J. Biol. Chem. 272, 19633\u201319636. https:\/\/doi.org\/10.1074\/jbc.272.32.19633 (1997).","journal-title":"J. Biol. Chem."},{"key":"20075_CR40","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/cas.12176","volume":"104","author":"Y Zhu","year":"2013","unstructured":"Zhu, Y. et al. Sunitinib induces cellular senescence via p53\/Dec1 activation in renal cell carcinoma cells. Cancer Sci. 104, 1052\u20131061. https:\/\/doi.org\/10.1111\/cas.12176 (2013).","journal-title":"Cancer Sci."},{"key":"20075_CR41","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00204-019-02511-9","volume":"93","author":"B Kopp","year":"2019","unstructured":"Kopp, B., Khoury, L. & Audebert, M. Validation of the gammaH2AX biomarker for genotoxicity assessment: A review. Arch. Toxicol. 93, 2103\u20132114. https:\/\/doi.org\/10.1007\/s00204-019-02511-9 (2019).","journal-title":"Arch. Toxicol."},{"key":"20075_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 108, 73\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-380888-2.00003-0 (2010).","journal-title":"Adv. Cancer Res."},{"key":"20075_CR43","doi-asserted-by":"publisher","first-page":"14728","DOI":"10.1038\/ncomms14728","volume":"8","author":"AR Barr","year":"2017","unstructured":"Barr, A. R. et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat. Commun. 8, 14728. https:\/\/doi.org\/10.1038\/ncomms14728 (2017).","journal-title":"Nat. Commun."},{"key":"20075_CR44","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","volume":"59","author":"TM Pawlik","year":"2004","unstructured":"Pawlik, T. M. & Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 928\u2013942. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.03.005 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"20075_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen, J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb. Perspect. Med. 6, a026104. https:\/\/doi.org\/10.1101\/cshperspect.a026104 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"20075_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/cdd.2017.172","volume":"25","author":"K Engeland","year":"2018","unstructured":"Engeland, K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 25, 114\u2013132. https:\/\/doi.org\/10.1038\/cdd.2017.172 (2018).","journal-title":"Cell Death Differ."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20075-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20075-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20075-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T06:21:49Z","timestamp":1668666109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20075-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20075"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20075-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19752"}}